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Mesenchymal stem cells (MSCs) hold great promise
for therapeutic use in regenerative medicine and
tissue engineering. A detailed understanding of the
molecular processes governing MSC fate determination
will be instrumental in the application of MSCs. Much
progress has been made in recent years in defining the
epigenetic events that control the differentiation of
MSCs into different lineages. A complex network of
transcription factors and histone modifiers, in concert
with specific transcriptional co-activators and
co-repressors, activates or represses MSC differentiation.
In this review, we summarize recent progress in
determining the effects of histone-modifying enzymes
on the multilineage differentiation of MSCs. In addition,
we propose that the manipulation of histone signatures
associated with lineage-specific differentiation by small
molecules has immense potential for the advancement
of MSC-based regenerative medicine.enzymes
Epigenetic mechanisms play a pivotal role in the promo-Introduction
Mesenchymal stem cells (MSCs) have been emerging as
an extremely promising therapeutic agent for tissue re-
generation and diseases largely because of their multi-
potent properties and capacity for self-renewal. Stem cell
self-renewal and differentiation require selective activa-
tion or silencing of specific transcription programs in
response to environmental cues. This is achieved by inten-
sive crosstalk between transcription factors and epigenetic
modulators regulating the chromatin conformation that
affects access of the transcriptional machinery to spe-
cific gene promoters. In contrast to growing information* Correspondence: xjiang@cuhk.edu.hk
1Key Laboratory for Regenerative Medicine, Ministry of Education, Epithelial
Cell Biology Research Centre, School of Biomedical Sciences, Lo Kwee-Seong
Integrated Biomedical Sciences Building, Shatin, New Territories, Hong Kong,
PR China
3Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The
Chinese University of Hong Kong, Hong Kong, SAR, China
Full list of author information is available at the end of the article
© 2015 Huang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.concerning transcriptional regulation, the epigenetic
mechanisms governing MSC identity and fate deter-
mination are not well understood and remain an active
area of investigation.
Within the context of chromatin, numerous histone-
modifying enzymes reciprocally collaborate to establish
and maintain a heritable epigenetic code by addition or
removal of an array of covalent modifications in the core
histones and other chromatin proteins. These modifica-
tions regulate gene expression as well as other genomic
functions, and have been implicated in the defining of
cell identity and fate. In this review, we summarize our
current understanding of how histone-modifying en-
zymes modulate multi-lineage differentiation of MSCs.
In addition, we discuss how an advanced understanding
of epigenetic regulatory mechanisms will provide novel
avenues for MSC-based therapy.Histone modification and histone-modifying
tion of divergent transcriptional pathways during both
embryonic development and adult tissue maintenance.
Regulation of gene expression at the epigenetic level oc-
curs via modifications of chromatin architecture by fa-
cilitating the opening of DNA (euchromatin) to permit
transcription, or the condensing of DNA (heterochromatin)
to repress transcription [1]. Therefore, the architecture
of chromatin is essential for the regulation of various
chromatin-based cellular processes, and is dynamically
modulated through the orchestration of multiple mecha-
nisms, including histone modification, DNA methylation,
chromatin remodeling, and non-coding RNA. Among
these mechanisms, post-translational histone modifica-
tions, such as methylation, acetylation, phosphorylation,
ADP-ribosylation and ubiquitination, play a central
role and have been extensively studied over the past
two decades. These modifications are brought about by
a series of ‘writing’ and ’erasing’ events executed by
histone-modifying enzymes [2]. Histone-modifying enzymesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of covalent histone modifications, which subsequently
function as a ‘histone code’ that would be recognized by
chromatin effector molecules (‘reader’), causing the re-
cruitment of other molecules to alter the chromatin and/
or transcription states [2,3]. Various groups of histone-
modifying enzymes supplement (writer) or eliminate
(eraser) covalent modifications to histone proteins. For in-
stance, histone methyltransferases (HMTs) and histone
acetyltransferases (HATs) supplement methyl and acetyl
groups, respectively, whereas histone demethylases
(HDMs) and histone deacetylases (HDACs) remove me-
thyl and acetyl groups, respectively. The discovery of these
enzymes represents a milestone in understanding the bio-
logical functions underlying histone modifications because
they provide direct evidence linking histone conformationTable 1 Epigenetic readers, writers and erasers
Family Activity Major catalytic si
Writers
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HDAC, histone deacetylase; PRMT, protein arginine methyltransferases; PWWP dom
PHD domain, Cys4-His-Cys3 motif.states and transcriptional regulation. The categories, spe-
cificity and mechanisms of various histone-modifying en-
zymes have been extensively reviewed elsewhere [4-6]. In
this review, we mainly focus on the role of histone-
modifying enzymes in the regulation of MSC multi-
lineage differentiation, with emphasis on histone acetyl-
ation, histone methylation and their corresponding
histone-modifying enzymes. A list of histone writers,
erasers and readers and their corresponding catalytic sites
is provided in Table 1.
Histone-modifying enzymes regulate
mesenchymal stem cell multi-lineage
differentiation
MSCs, also referred to as multipotent stromal cells or mes-
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ain, Pro-Trp-Trp-Pro motif; MBT domain, malignant brain tumor domain;
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for regenerative therapies. At present, a large number of
studies are focusing on identifying extrinsic regulators and
their intrinsic target transcription factors that regulate
MSC properties and functions, whereas very little is
known regarding the epigenetic events that control MSC
identity and/or functions. Indeed, accumulating evidence
indicates that cell fate and function are determined by
DNA-binding transcription factors that are regulated
more specifically at the epigenetic level, as we learned
from pluripotent stem cells such as embryonic stem (ES)
cells and induced-pluripotent stem cells [7,8]. Furthermore,
ES cells have been widely used as a model to decipher the
epigenetic mechanisms of cell fate determination and cell
homeostasis. The pluripotent capacity of ES cells correlates
with the requirements of dynamic genomic organization
to support their functional plasticity. Genes that are in-
volved in maintaining both repressive (H3K27me3) and
activating (H3K4me3) histone modifications are important
in ES cells for early lineage commitment. These bivalent
genes, which encode mainly transcriptional factors in-
volved in lineage specification, such as Sox, Fox, Pax, Irx,
and Pou gene family members, are considered to be
poised for rapid activation in response to appropriate dif-
ferentiation signals [9,10].
Like ES cells, several adult tissues, including sperm,
testis, cerebellum, and the hematopoietic compartment,
have been reported to contain bivalent chromatin domains
as well [11-13]. For instance, during hematopoietic stem
cell differentiation, most genes associated with bivalent
chromatin states remain silent and lose the H3K4me3
mark after differentiation. In contrast, genes without the
H3K27me3 mark are associated with increased levels of
H2A.Z, H3K4me1, H3K9me1, H4K20me1 and RNA poly-
merase II, and become activated after differentiation [11].
Thus, it is plausible that many chromatin regulatory factors
that have been identified to control ES cell fates play simi-
lar roles in adult stem cells. For MSCs, while it is still un-
clear whether chromatin structure and histone-modifying
enzymes utilize similar mechanisms to modulate gene ex-
pression, emerging evidence indicates that histone modifi-
cations play an important role in the control of MSC
differentiation. Distinct histone-modifying enzymes asso-
ciated with MSC lineage conversion are listed in Table 2.
Tri-lineage differentiation of mesenchymal stem cells
Histone methyltransferases and histone demethylases
MSCs can be readily differentiated into osteoblasts, adi-
pocytes or chondrocytes, while directed differentiation
strictly relies on an orchestrated balance among these
three lineages. Growing evidence suggests that, upon
differentiation of MSCs, various histone modifications
change to facilitate the activation or repression of key
transcription factors, guiding development towards specifiedcell lineages (Figure 1). Among these modifications, his-
tone methylation is crucial for chromatin reorganization
and regulation of gene transcription. For example, lysine
(K) methylation at H3K9, H3K27, and H4K20 is associ-
ated with transcriptionally silenced chromatin, while
methylation at H3K4, H3K36, and H3K79 is correlated
with transcriptionally active regions. The dynamic alter-
ation of histone methylation during lineage commitment
is achieved by the reciprocal action of HMTs and HDMs.
Furthermore, histone methylation has a role in osteo-
genic differentiation from MSCs. It has been shown that
HoxA10, a gene necessary for the embryonic patterning
of skeletal elements, contributed to osteogenic lineage
determination through enrichment of H3K4me3 at the
promoter region [14]. Increased HoxA10 activated
Runx2, alkaline phosphatase and osteocalsin (OC) dur-
ing osteogenic differentiation [14]. While this study did
not identify the specific HMTs responsible for the en-
richment of H3K4Me3, our work provided a direct link
between histone methylation and transcriptional activa-
tion of master osteogenic transcription factors. Direct
evidence showing the role of HMT in osteogenesis is
provided by another study demonstrating that ESET
(also known as SETDB1, a HMT methylating histone H3
at lysine 9) regulates the osteogenic differentiation of
MSCs during postnatal bone development [15]. Overex-
pression of ESET deregulates Runx2 and Indian hedge-
hog (Ihh), both well known for their critical roles in the
osteogenic and chondrogenic differentiation of MSCs.
The function of PcG (polycomb group) proteins in osteo-
genic differentiation of MSC has also been investigated.
Additionally, PcG proteins form multi-protein complexes
(termed polycomb-repressive complexes, PRCs) to regulate
chromatin structure and dynamically change gene expres-
sion during differentiation [16]. Genome-wide investigation
of EZH2 (one of the subunits of PRC2, which specifically
trimethylates H3K27me3) target genes showed that over
4,000 genes bound EZH2 before differentiation, whereas
less than 30 genes were bound after osteogenic differenti-
ation with a concomitant decrease in the H3K27me3 mark
[17]. In addition, the study reported that activation of
cyclin-dependent kinase 1 (CDK1) promoted osteogenic
differentiation through disruption of the PRC2, which
subsequently led to the activation of Runx2 expression
during osteogenesis. Altogether, this study suggests that
the EZH2-mediated decrease in H3K27me3 binding dur-
ing osteogenic differentiation might favor the activation of
lineage-specific genes. It is to be noted that several HMTs
have been reported to regulate adipogenesis. For instance,
knockdown of SETDB1, a H3K9 methyltransferase, pro-
moted adipogenic differentiation by decreasing H3K9me2
and increasing H3K4me2 levels [18]. It was also reported
that MLL3/MLL4 (methyltransferases of histone H3 Lys4)
were involved in the establishment of an ASCOM complex
Table 2 Distinct histone-modifying enzymes associated with multi-lineage differentiation of mesenchymal stem cells






Enhancer of Zeste homology 2 EZH2 HMT H3K27me3 Promoting adipogenesis [17,23,41]
Inhibiting neurogenesis
Inhibiting osteogenesis
Lysine demethylase 6A KDM6A HDM H3K27me3 Promoting osteogenesis [23]
ERG-associated protein
with a SET domain
ESET (SETDB1) HMT H3K9me2/3 Promoting adipogenesis [15,18]
Inhibiting osteogenesis
Lysine demethylase 4B KDM4B HDM H3K9me3 Promoting osteogenesis [22]
Lysine demethylase 6B KDM6B HDM H3K27me3 Promoting osteogenesis [22]
Plant homeodomain finger 2 Phf2 HDM H3K9me2 Promoting adipogenesis [21,24,29]
Promoting chondrogenesis
Lysine demethylase 2A KDM2A (FBXL11) HDM H3K36me2 Inhibiting osteo/dentinogenesis [27,28]
H3K4me3
PR-Set7 (SETD8, SET8, KMT5A) PR-Set7/Setd8 (SET8) HMT H4K20me1 Promoting adipogenesis [20]
Mixed-lineage leukemia H3K4
methyltransferase protein
MLL3/MLL4 HMT H3K4me3 Promoting adipogenesis [19]
Lysine-specific demethylase 1 LSD1 HDM H3K4/K9 Promoting adipogenesis [18]
Histone acetylation
Histone deacetylases 2 HDAC2 HDAC H3K9/K14ac Modulating osteogenesis [37,46]
Inhibiting cardiomyogenesis
Histone deacetylases 1 HDAC1 HDAC H3K9/K14ac Inhibiting adipogenesis [37,38,46]
Inhibiting cardiomyogenesis
Histone deacetylases 6 HDAC6 HDAC H3K9/K14ac/H4K8ac Promoting adipogenesis [39]
CREB binding protein and p300 CBP/p300 HAT H3K9/K14/K56ac Promoting chondrogenesis [32,33,40]
H4K5/K8ac Promoting adipogenesis
Tat-interactive protein 60 kDa Tip60 HAT H2AK5ac Promoting adipogenesis [34,35]
General control nonrepressed
protein 5




HAT, histone acetyltransferase; HDAC, histone deacetylase; HDM, histone demethylase; HMT, histone methyltransferase.
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interacted with peroxisome proliferator-activated receptor
(PPAR)-γ and promoted adipogenesis [19]. This idea was
further supported by findings that mice expressing inacti-
vated MLL3 exhibited decreased adipose tissue [19]. Apart
from that, PR-Set7/Setd8, the histone H4 Lys20 (H4K20)
monomethyltransferase, was shown to modulate adipo-
genesis through PPAR-γ and its partner protein, retinoid
X receptor-α, via a positive feedback loop [20].
Recently, distinct HDMs have been identified as crit-
ical regulators of MSCs differentiation [18,21-24]. Dur-
ing adipocyte differentiation, expression of the H3K4/
K9 demethylase LSD1 was upregulated and knockdown
of LSD1 resulted in impaired adipocyte differentiation
of 3 T3-L1 preadipocytes by decreasing H3K4me2
levels while increasing H3K9me2 levels at the promoter
region of the CEBPα gene [18]. Another H3K9me2demethylase, Phf2, was recently identified as a positive
regulator in adipogenesis by coactivating both C/EBPα
and C/EBPΔ [21,24]. The critical role of H3K9 demethyla-
tion has been further validated by a study showing mice
carrying a disruption in the gene encoding Jhdm2a, an-
other H3K9 demethylase, exhibit obesity and hyperlipid-
emia [25]. On the other hand, it was shown recently that
the histone demethylases KDM4B and KDM6B play crit-
ical roles in osteogenic commitment of MSCs by remov-
ing H3K9me3 and H3K27me3. Depletion of KDM4B or
KDM6B significantly reduced osteogenic differentiation
and increased adipogenic differentiation. Mechanistically,
while KDM6B was required for the expression of HOX
genes by removing H3K27me3, KDM4B regulated the ex-
pression of DLX genes by removing H3K9me3 [22]. This
study provides convincing evidence that HDMs play vital
roles in governing lineage-specific decisions during MSC
Figure 1 A variety of histone-modifying enzymes are involved in the dynamic regulation of mesenchymal stem cell (MSC) differentiation
into adipocytes, osteocytes or chondrocytes.
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leagues [23] further revealed that the reciprocal action of
EZH2 and KDM6A could coordinate to achieve an epi-
genetic switch in human MSC differentiation. EZH2 spe-
cifically trimethylated H3K27me3, whereas KDM6A
removed the methyl group from H3K27me3. Conse-
quently, while inhibition or knockdown of EZH2 resulted
in decreased adipogenesis and increased osteogenesis,
knockdown of KDM6A led to increased adipogenesis and
decreased osteogenesis. Of great importance, EZH2 and
KDM6A affected the same group of master regulatory
genes involved in adipogenesis and osteogenesis, including
those encoding PPARγ, CEBPα, Adipsin, Runx2, OC and
osteopotin [23]. These findings demonstrate that epigen-
etic shifts centered on H3K27me3 determine MSC fate via
coordinated modification by both HMTs and HDMs. The
importance of HDMs in MSC osteogenic differentiation
has been further demonstrated in another study investi-
gating the molecular basis of a rare human genetic disease,
oculo-facial-cardio-dental syndrome [26]. It was reported
that BCL-6 co-repressor (BCOR) mutation increased his-
tone H3K4 and H3K36 methylation via KDM2A in MSCs,
thereby reactivating transcription of AP-2α, leading to in-
creased osteo-dentinogenic potential of MSCs in oculo-
facial-cardio-dental syndrome patients [27]. KDM2A is
also involved in other lineage differentiation of MSCs. De-
pletion of KDM2A enhanced the adipogenic and chondro-
genic differentiation potential by upregulating SOX2 and
NANOG [28]. Compared with osteogenic and adipogenic
differentiation, few published studies have reported on
epigenetic regulation of chondrogenic differentiation
from MSCs. A recent study using a mouse model re-
vealed that AT-rich interactive domain 5b (Arid5b)
functioned as a transcriptional co-regulator of Sox9 andrecruited Phf2 to the promoter region of Col2a1 and aggre-
can, promoting the demethylation of H3K9me2 specifically
in these genes [29].
Histone acetyltransferases and histone deacetylases
Histone acetylation is one of the most abundant and dy-
namic histone modifications. The actual level of histone
acetylation is dependent on highly orchestrated interplay
between HATs and HDACs. Numerous studies have re-
ported the involvement of histone acetylation in regulat-
ing lineage-specific gene expression in MSCs. Shen and
colleagues [30] observed that both the promoter and
coding regions of the OC gene contained low levels of
acetylation of histone H3 and H4 during the proliferative
period of osteogenic differentiation when this gene was
inactive. However, OC became active in the mature oste-
oblasts, which correlated with enriched H4 acetylation,
providing the link between osteogenic differentiation
and histone acetylation. Subsequently, ChIP-on-chip
analysis revealed that H3K9Ac correlated with activating
genes and H3K9me2 was associated with silencing genes
in osteogenic differentiation from MSCs. This study also
found that many vitamin D receptor elements were at
the gene promoters in both H3K9Ac-decreased and
H3K9me2-increased groups, suggesting that the vitamin
D receptor might be a potential regulator mediating dea-
cetylation and dimethylation of H3K9 during osteogenic
differentiation [31]. Histone acetylation is also associated
with chondrocyte differentiation. It has been reported
that several transcription factors and co-activators, such
as Scleraxis/E47 and p300, cooperatively modulate Sox9-
dependent transcription by interacting with Sox9. The
Sox9- related transcriptional apparatus activates its tar-
get gene expression through p300- mediated histone
Huang et al. Stem Cell Research & Therapy  (2015) 6:35 Page 6 of 9acetylation on chromatin during chondrogenesis [32,33].
In addition, HATs p300/CBP and Tip60 have been shown
to promote the expression of adipogenic genes through
direct interaction with PPAR-γ [34,35]. Specifically, the
two homologous cofactors p300 and CBP bind to the
amino terminus of PPARγ2 in a ligand-independent man-
ner, leading to further recruitment of HATs that appropri-
ately modify the surrounding chromatin, allowing the
transcriptional machinery access to the gene promoter
[36]. Thus, these studies in cultured cells have shown that
lineage-associated core transcription factors interact with
HATs, which stimulate transcription by acetylating nu-
cleosomal histones, thereby relaxing the chromatin struc-
ture and facilitating transcription.
On the other hand, HDACs, a conserved family of
chromatin-modifying enzymes that repress transcription
by deacetylating nucleosomal histones, are also associ-
ated with key transcription factors, counteracting the
functions of HATs. For instance, through the systematic
genetic deletion of HDAC genes in cultured mesenchy-
mal precursor cells, Haberland and colleagues showed
that deletion of HDAC1 and HDAC2 led to reduced
lipid accumulation, validating the redundant and requis-
ite roles of class I HDACs in adipogenesis [37]. The
regulatory role of class I HDAC in lineage commitment
was further strengthened by the recent finding that
HDAC1 specifically occupied the −1,286 to −1,065 bp
promoter region of the C/EBPα gene during adipogene-
sis [38]. In contrast, HDAC6, a representative of class II
HDACs, has been shown to promote adipogenesis, yet
inhibits osteogenesis in human adipose tissue-derived
MSCs. Overexpression of miR-22, which directly targetsFigure 2 Several histone-modifying enzymes participate in the re
cells (MSCs).HDAC6, repressed the expression of adipogenic tran-
scription factors whereas it upregulated the expression
of osteogenic genes, indicating a positive role of HDAC6
in adipogenesis [39]. Of particular interest, it has been
observed recently that HATs and HDACs are involved
in the regulation of the same transcription factor
through the modification of histones, and also the regu-
lation of each other during lineage commitment. During
chondrogenesis, YY1 and p300 competitively bind to the
core promoter region of ChM-I (the chondromodulin-I
gene). In particular, YY1 (a transcriptional repressor) es-
tablishes and maintains transcriptional silencing by
recruiting HDACs while p300 promotes the expression
of ChM-I through cooperation with Sp3 [40], indicating
HAT and HDAC can compete for the same promoter re-
gion of lineage-associated genes.
Trans-lineage differentiation of mesenchymal stem cells
MSCs have the ability to cross oligolineage boundaries
and differentiate into different kinds of cell types, such
as neurons, cardiomyocytes, hepatocytes and endothelial
cells, under appropriate culture conditions, indicating
that they are more plastic than we previously thought.
While the molecular mechanisms underlying MSC
transdifferentiation are largely unknown, it is plausible
that epigenetic plasticity is one of the major factors con-
tributing to this unique feature of MSCs. Indeed, increas-
ing evidence has shown that both histone methylation and
acetylation are involved in the regulation of MSC transdif-
ferentiation (Figure 2). For example, during the neuronal
induction of MSCs, EZH2 negatively regulates neuronal
differentiation by binding to the promoter region ofgulation of trans-lineage differentiation of mesenchymal stem
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EZH2 activates PIP5K1C and increases the intracellular
Ca2+ level via the PI3-kinase/Akt signaling pathway, which
ultimately leads to the neuronal differentiation of MSCs
both in vitro and in vivo [41]. Interestingly, HDACs are
also involved in the neurogenesis of MSCs, with a HDAC
inhibitor such as valproic acid significantly stimulating the
expression of the neural progenitor markers Nestin,
Musashi, CD133, and GFAP in bone marrow-derived
MSCs, promoting neuronal differentiation [42]. Valproic
acid can also considerably improve the hepatic differen-
tiation of bone marrow-derived MSCs [43]. Histone
modifiers also control the differentiation of MSCs into
mesoderm cell lineages. During 5-azacytidine-induced
cardiomyocyte differentiation, Gcn5 (a HAT) increases
the level of histone acetylation on the promoter regions
of the early cardiomyocyte-specific genes GATA4 and
NKx2.5, and accelerates differentiation [44]. In contrast,
suppression of HDAC1 or HDAC2 by small interfering
RNAs enhances acH3 and acH4 levels and upregulates
cardiac-specific gene expression in MSCs [45]. More-
over, a recent report showed that the epigenetic modifying
drug BIX-01294 (a histone G9a methyltransferase inhibitor)
improved endothelial differentiation of adipose tissue-
derived MSCs through upregulation of several endothelial
markers and factors associated with blood vessel formation,
such as VCAM-1, PECAM-1, von Willebrand factor, and
VEGFR-2 [46]. Taken together, these studies provide a dee-
per insight into the epigenetic mechanisms controlling
MSC fate determination, and suggest molecular models of
how key lineage-associated transcriptional factors are linked
to histone modifications in MSCs.
Development of small molecules targeting
histone-modifying enzymes
The knowledge obtained from epigenetic studies on MSC
differentiation could be applied to regenerative medicine.
Indeed, it is conceivable that manipulation of the epigen-
etic signatures associated with lineage-specific differenti-
ation can direct patient-specific therapy. For instance, as
chemically modifiable enzymes, KDM4B and KDM6B
could be activated or deactivated to regulate specific
lineage decisions of MSCs, thereby holding promising
potential as therapeutic targets for stem cell-mediated
regenerative medicine as well as the treatment of hu-
man metabolic diseases such as osteoporosis and obes-
ity [22]. In this regard, screening and development of
small molecules specifically targeting histone-modifying
enzymes could be a feasible strategy. Indeed, many che-
micals targeting HATs or HDACs have been developed
and have undergone clinical trials [47]. In particular,
various HDAC inhibitors have been used in various clin-
ical trials to treat different cancers and have shown prom-
ising results alone or in combination with conventionaloncological modalities [48]. Furthermore, drugs targeting
HMTs and HDMs are being developed. For example, a
specific inhibitor of Suv39 HMT was identified [49] and,
more recently, GSK 126, which inhibits EZH2, was devel-
oped to suppress the growth of lymphoma [50]. In general,
a more defined understanding of the epigenetic mecha-
nisms underlying MSC fate determination would be es-
sential for the development of small molecules and their
ultimate application in regenerative medicine. On the
other hand, it would be essential to evaluate the adverse
effects of such molecules because almost all histone-
modifying enzymes are ubiquitously expressed regardless
of tissue or cell type.
Conclusion
It is quite apparent that significant progress has been
made during the past few years in identifying the histone-
modifying enzymes involved in the fate determination
processes of MSCs. These functional enzymes fine-tune
epigenetic environments at regulatory regions of multiple
transcriptional factors and are closely related to gene acti-
vation/repression. The challenge for the future is to gain
more insights into the global epigenetic regulatory mecha-
nisms governing the commitment of MSCs to specified
lineages. In this regard, research into MSCs lags far behind
that of pluripotent stem cells since a very limited number
of studies have been designed to determine epigenetic sig-
natures during MSC lineage commitment. While one ana-
lysis of genes regulating adipogenic differentiation of
human MSCs has revealed dynamic changes in histone
marks reminiscent of those seen in ES cells [51], other
studies have found that histone modifications were glo-
bally stable throughout differentiation but showed distinct
and highly dynamic distribution patterns at specific genes,
indicating that, unlike pluripotent stem cells, histone
modifications in MSCs appear to be gene-specific [52,53].
Ideally, by using whole-genome chromatin immunopre-
cipitation and deep sequencing, defined studies will open
up a new epigenetic landscape in MSCs. In addition, more
comprehensive studies aiming to understand how various
epigenetic elements compile and coordinate to achieve
lineage commitment are necessary. Considering the fact
that epigenetic research is paving the way for many new
breakthroughs in the prevention, diagnosis and treatment
of human diseases, focused efforts on the detailed mecha-
nisms linking epigenetic regulatory mechanisms to adult
stem cell function in physiological/pathological conditions
have an immense potential for improving human health
and welfare.
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